U
ALNY icon

UBS’s Alnylam Pharmaceuticals ALNY Stock Holding History

UBS’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$86K Sell
1,100
-1,000
-48% -$64.5K ﹤0.01% 6166
2014
Q2 		$133K Buy
2,100
+1,800
+600% +$107K ﹤0.01% 5614
2014
Q1 		$20K Sell
300
-600
-67% -$46.5K ﹤0.01% 8059
2013
Q4 		$58K Sell
900
-8,900
-91% -$531K ﹤0.01% 6760
2013
Q3 		$627K Buy
+9,800
New +$488K ﹤0.01% 3873

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

UBS's ALNY Position: Q3 2014 in Review

UBS reduced its Alnylam Pharmaceuticals (ALNY) stake by 52% in Q3 2014, selling an estimated $2.44M and leaving 35,563 shares worth $2.78M. The position accounts for ﹤0.01% of the portfolio, ranked #2596.

UBS first reported a position in ALNY in Q2 2013 and has held it in 6 quarters since. The position peaked at $4.63M in Q2 2014. 186 funds tracked by Wall St. Rank hold ALNY as of Q3 2014.

  • UBS held 35,563 shares of Alnylam Pharmaceuticals worth $2.78M as of Q3 2014.
  • UBS sold 37,793 Alnylam Pharmaceuticals shares in Q3 2014, an estimated $2.44M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2596 holding.
  • UBS first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Alnylam Pharmaceuticals position peaked at $4.63M in Q2 2014.
  • 186 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.